Atara Biotherapeutics (ATRA) Share-based Compensation (2013 - 2026)
Atara Biotherapeutics (ATRA) posted Share-based Compensation of $749000.0 for Q1 2026, down 50.63% on a QoQ basis from $1.5 million in Q4 2025, and down 82.2% year-over-year from $4.2 million in Q1 2025.
Atara Biotherapeutics (ATRA) Share-based Compensation (2013 - 2026) Analysis & Trends
Atara Biotherapeutics' Share-based Compensation history runs 14 years deep, the most recent figure standing at $749000.0 for Q1 2026.
- Quarterly Share-based Compensation fell 82.2% year-over-year to $749000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.7 million (down 66.25% YoY) and the FY2025 annual result came in at $9.8 million, down 63.88% from the prior year.
- Share-based Compensation was $749000.0 for Q1 2026 at Atara Biotherapeutics, down from $1.5 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $14.1 million in Q2 2022 and bottomed at $93000.0 in Q1 2023.
- A 5-year average of $5.8 million and a median of $5.8 million in 2024 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation tumbled 94.98% — and 2024, when it jumped 8929.03%.
- Atara Biotherapeutics' Share-based Compensation stood at $14.0 million in 2022, then declined by 20.54% to $11.1 million in 2023, then sank by 47.54% to $5.8 million in 2024, then slumped by 74.05% to $1.5 million in 2025, then sank by 50.63% to $749000.0 in 2026.
- Business Quant data shows ATRA's Share-based Compensation at $749000.0 in Q1 2026, $1.5 million in Q4 2025, and $1.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 305,000.00 |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 9.26 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 87.30 Mn |
| 10 | Atara Biotherapeutics | 110.04 Mn | 101.68 Mn | 392,000.00 | 749,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 749,000.00 |
| Mar 31, 2026 | 749,000.00 |
| Dec 31, 2025 | 1.52 Mn |
| Dec 31, 2025 | 1.52 Mn |
| Sep 30, 2025 | 1.23 Mn |
| Sep 30, 2025 | 1.23 Mn |
| Jun 30, 2025 | 400,000.00 |
| Jun 30, 2025 | 400,000.00 |
| Mar 31, 2025 | 4.21 Mn |
| Mar 31, 2025 | 4.21 Mn |
| Dec 31, 2024 | 5.85 Mn |
| Dec 31, 2024 | 5.85 Mn |
| Sep 30, 2024 | 6.42 Mn |
| Sep 30, 2024 | 6.42 Mn |
| Jun 30, 2024 | 6.34 Mn |
| Jun 30, 2024 | 6.34 Mn |
| Mar 31, 2024 | 8.40 Mn |
| Mar 31, 2024 | 8.40 Mn |
| Sep 30, 2023 | 11.14 Mn |
| Sep 30, 2023 | 11.14 Mn |